Effects of deficient mismatch repair on the prognosis of patients with ...

These results indicate that dMMR patients can obtain benefit from long-term chemotherapy. However, a part of dMMR patients died during the ...

MMR status as a prognostic marker for patients with stage II disease. Among the stage II colon cancer patients, 193 had dMMR. The OS rate of ...

Effects of deficient mismatch repair on the prognosis of patients with ...

The benefits of dMMR in stage III patients were observed from the second postoperative year until the end of follow-up.

Prognostic implications of mismatch repair deficiency in patients with ...

DMMR was associated with improved outcomes in patients with nonmetastatic endometrial cancer, but not in patients with nonmetastatic colorectal cancer who ...

Prognostic Impact of Deficient DNA Mismatch Repair in Patients ...

Conclusion. The prognostic impact of MMR depended on tumor site, and this interaction was validated in an independent cohort. Among dMMR cancers, proximal ...

Prognostic Effect of Mismatch Repair Status in Early-Stage ...

Deficient MMR status is associated with significantly decreased RFS in patients with early-stage EEC who receive adjuvant radiation therapy. OS was not affected ...

The Impact of Mismatch Repair Status on Prognosis of Patients With ...

In colorectal cancer, MSI-H/dMMR tumor shows better prognosis, and may be associated with lack of benefit from adjuvant chemotherapy in stage II disease (16, 17) ...

Implications of mismatch repair-deficient status on management of ...

Among dMMR/MSI CRCs, BRAFV600E mutation testing thus can be performed to distinguish LS cases from sporadic tumors (9). Patients with suspected hereditary CRC ...

Prognostic impact of deficient mismatch repair (dMMR) in 7,803 ...

Background: MMR status has been established as an important prognostic factor in CC pts. We determined the association of dMMR status with ...

Stage III deficient mismatch repair colon patients get greater benefit ...

By analyzing only TNM stage III dMMR colon cancer patients, we concluded that the significant prognostic risk factors were old age, positive ...

Loss of survival advantage for deficient mismatch repair in patients ...

Patients with stage II deficient mismatch repair (dMMR) show a better prognosis than patients with colorectal cancer (CRC) with proficient ...

Prognostic impact of high-risk factors and KRAS mutation in patients ...

Background: Deficient mismatch repair (dMMR) is associated with a good prognosis in patients with stage II colon cancer and observation is ...

Deficient mismatch repair/microsatellite unstable colorectal cancer

Microsatellite unstable (MSI) colorectal cancers (CRCs) are due to DNA mismatch repair (MMR) deficiency and occurs in15% of non-metastatic diseases and 5% ...

Mismatch Repair Deficiency, Microsatellite Instability, and Survival ...

In contrast, patients treated with chemotherapy plus surgery who had either high MSI or MMRD had a median OS of 9.6 months (95% CI, 0.1-22.5 ...

Survival benefit with adjuvant chemotherapy in stage III ... - Nature

Clinical observations have demonstrated that microsatellite instability-high (MSI-H) and/or deficient MMR (dMMR) status are associated with ...

Survival of Patients with Deficient Mismatch Repair Versus Proficient ...

dMMR mCRC forms a poorer biological subgroup with distinct prognostic, predictive, and therapeutic implications compared with proficient ...

(PDF) Effects of deficient mismatch repair on the prognosis of ...

Conclusion The benefits of dMMR in stage III patients were observed from the second postoperative year until the end of follow-up. However, the ...

SO-23 Prognostic impact of microsatellite instability/mismatch repair ...

Our data indicate that MSI-H status has no prognostic impact on the OS of patients with either stage III colon cancer or stage IV CRC.

Clinical Implications of Mismatch Repair Status in Patients With High ...

Prognostic value of MSI and factors affecting survival outcomes. With a median follow-up duration of 25.0 (6.4-80.0) months, the estimated 3-year DFS and OS ...

Survival outcome of adjuvant chemotherapy in deficient mismatch ...

The prognostic impact of DNA mismatch repair (MMR) status remains controversial in patients with stage III colon cancer who are treated with ...